Illumina Stock News

Shares of Illumina Inc. ILMN, -3.36% fell after hours on Thursday after the maker of DNA-sequencing technology cut its full-year sales and profit outlook. The company said it now expected full-year sa

One knock against Wall Street analysts is they're too bullish, especially when it comes to Nasdaq 100 stocks. No matter the market conditions, they seem able to find the silver lining.

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Illumina (ILMN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the q

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Ligand Pharmaceuticals (LGND) or Illumina (ILMN). But which of these two companies is the bes

Investors need to pay close attention to Illumina (ILMN) stock based on the movements in the options market lately.

Activist-investor Carl Icahn said his firm had sued current and former board directors at Illumina concerning the acquisition of gene-sequencing company Grail , the Financial Times reported on Tuesday

Illumina Inc. ILMN, -1.10% responded Friday to an order it received Thursday from the European Commission directing the company to divest its $7.1 billion acquisition of cancer-test maker Grail. Illum

Illumina said on Friday it would divest cancer test maker Grail in 12 months, according to the terms of the order by the European Commission, if it does not win its challenge in court.

Illumina Inc (NASDAQ:ILMN), a genetic testing company, has been ordered by EU antitrust regulators to sell Grail after closing its takeover of the cancer test maker before securing their approval. In

U.S. genetic testing company Illumina has been ordered by EU antitrust regulators to sell cancer test maker Grail after it completed the deal before securing their approval.

Illumina Inc said on Wednesday it will divest Grail if the company loses the final appeals in U.S. or European courts.

U.S. genetic testing company Illumina will on Thursday get an order from EU antitrust regulators to sell cancer test maker Grail , a year after the $7.1 billion deal was blocked, a person with direct

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Ligand Pharmaceuticals (LGND) or Illumina (ILMN). But which of these two stocks presents inve

An order from EU competition regulators for Illumina to sell cancer detection test maker Grail could come as early as next week, the Financial Times reported on Monday, citing people with knowledge of

Illumina ( ILMN ), the maker of million-dollar genome sequencing machines that revolutionized the fields of genetics and biotechnology, has fallen hard in the past year. And some analysts believe the